Richard Jameson assumes position as Camurus’ Chief Commercial Officer
Lund — 20 June 2016 — Further to the announcement on December 14, 2015, Camurus (NASDAQ STO: CAMX) today announces that Richard Jameson has assumed the position of Chief Commercial Officer and member of the Executive Management Team.
Richard Jameson has broad experience from different commercial roles including sales leadership, marketing, market access and general management across a number of specialty pharmaceutical companies, including, Serono, Schering Plough and Ferring. In 2010 he joined Indivior (then Reckitt Benckiser Pharmaceuticals) as General Manager for Northern Europe (UK and Nordics) and led the building of the regional commercial team after the buyback of the buprenorphine franchise from Schering Plough. For the last three years he has been serving as Area Director EMEA at Indivior and was responsible for the leadership of a commercial organization across Europe, the Middle-East and Africa, focusing on the buprenorphine franchise (Subutex® and Suboxone®) and the treatment of opioid dependence. He was also a part of the leadership group for the demerger of Indivior from Reckitt Benckiser PLC in 2014.
“Richard brings a wealth of experience in commercial strategy, marketing and general management to Camurus at a time when we are expanding our business and starting the build-up of our commercial organization in Europe” said Fredrik Tiberg, President and CEO, Camurus.” His knowledge of the evolving European markets and previous commercialization successes within addiction and other specialty indication areas will serve us well as we prepare for the anticipated approval and launch of our long-acting buprenorphine products for treatment of opioid dependence."
“I am delighted to join the successful team at Camurus at this exciting stage of the company’s development” said Richard Jameson, Chief Commercial Officer “I look forward to initiating the commercialization of our innovative specialty medicines. The initial focus will be on ensuring that opioid dependent patients in Europe will have access to our weekly and monthly buprenorphine products, CAM2038, currently being assessed in a global Phase 3 program. The products represent the first innovation in this field for more than a decade, with the potential to transform the treatment of patients with opioid dependence.”
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com .
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92
The information was submitted for publication at 8.00 a.m. on 20 June 2016.